Status:
NO_LONGER_AVAILABLE
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
Lead Sponsor:
RedHill Biopharma Limited
Conditions:
Cholangiocarcinoma
Cholangiocarcinoma Non-resectable
Eligibility:
All Genders
18+ years
Brief Summary
This is an expanded access program (EAP) for eligible participants who do not qualify for participation in, or who are otherwise unable to access, the ongoing clinical trial ABC-108. This program is d...
Eligibility Criteria
Inclusion
- Diagnosis of cholangiocarcinoma
- Ineligible to participate in the ABC294640 clinical trial for the treatment of cholangiocarcinoma or geographically inaccessible to the trial.
- Judged by the treating oncologist to be medically suitable for treatment with ABC294640
- Willing and able to provide written, signed informed consent
- Approval by RedHill of the treating oncologist's clinical trial experience for the purpose of making ABC294640 available
- Regulatory approval by the appropriate jurisdiction
Exclusion
- 1\. Any medical condition that may cause treatment with ABC294640 to be potentially harmful as judged by RedHill
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03414489
Last Update
March 18 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.